the diagnostic performance of the AlzoSure Predict assay and its link to established
Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain.
Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.
[This corrects the article DOI: 10.3389/fninf.2026.1821249.].
Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision.
A major trial to test whether an experimental drug could prevent Alzheimer’s in patients without symptoms has started recruiting in the UK. Jacqui Wise examines the details
Mounting evidence suggests beta amyloid (Aβ) is not the sole initiating driver of cognitive decline in Alzheimer's disease (AD). This study explores whether there is an association between cognitive decline over eight years and Aβ.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
